NCT02254421 - Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 17, 2017

Study Completion Date

April 17, 2017

Conditions

Respiratory Syncytial Virus Infection

Interventions

DRUG

Presatovir

Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube

DRUG

Placebo

Placebo to match presatovir administered orally or via nasogastric tube

Trial Locations (17)

CHU de Bordeaux, Talence

City of Hope, Duarte

University of Chicago, Chicago

John Hopkins, Baltimore

Dana Farber Cancer Institute, Boston

University of Michigan, Ann Arbor

University of Minnesota, Minneapolis

New York Weill Cornell Medical Center, New York

Duke University, Durham

MD Anderson Cancer Center, Houston

Fred Hutchison Cancer Research Center, Seattle

Medical College of Wisconsin, Milwaukee

Hopital Saint-Louis, APHP, Paris

Hopital Foch, Suresnes

Seoul Saint Mary's Hospital, Seoul

Karolinska Institutet, Stockholm

University Clinical Basel, Basel